PT  - JOURNAL ARTICLE
AU  - Y Wang
AU  - H E Johnsen
AU  - S Mortensen
AU  - L Bindslev
AU  - R Sejersten Ripa
AU  - M Haack-Sørensen
AU  - E Jørgensen
AU  - W Fang
AU  - J Kastrup
TI  - Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention
AID  - 10.1136/hrt.2005.069799
DP  - 2006 Jun 01
TA  - Heart
PG  - 768--774
VI  - 92
IP  - 6
4099  - http://heart.bmj.com/content/92/6/768.short
4100  - http://heart.bmj.com/content/92/6/768.full
SO  - Heart2006 Jun 01; 92
AB  - Objective: To investigate the spontaneous occurrence of circulating mesenchymal stem cells (MSC) and angiogenic factors in patients with ST elevation acute myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). Design: In 20 patients with STEMI, blood samples were obtained on days 1, 3, 7, 14, 21, and 28 after the acute PCI. Fifteen patients with a normal coronary angiography formed a control group. MSC (CD45−/CD34−), plasma stromal derived factor 1 (SDF-1), vascular endothelial growth factor A (VEGF-A), and fibroblast growth factor 2 (FGF-2) were measured by multiparametric flow cytometry and enzyme linked immunosorbent assay (ELISA). Results: Circulating CD45−/CD34− cells were significantly decreased on day 7 compared with day 3. Cell counts normalised one month after the acute onset of STEMI. The changes were mainly seen in patients with a large infarction. Plasma SDF-1 increased significantly from day 3 to day 28, and VEGF-A and FGF-2 increased significantly from day 7 to day 28. Conclusions: Spontaneous sequential fluctuations in MSC and the increase in vascular growth factor concentrations after STEMI suggest that the optimal time for additional stem cell therapy is three weeks after a myocardial infarction to obtain the maximum effects by stimulating endogenous growth factors on the delivered stem cells.